Bausch + Lomb (BLCO) vs STAAR Surgical (STAA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Bausch + Lomb (BLCO) has outperformed STAAR Surgical (STAA) over the past year, gaining 28.6% versus a loss of 13.5%. Bausch + Lomb is the larger company by market cap ($6.93 billion vs $1.22 billion), about 5.7 times the size. On valuation, Bausch + Lomb trades at a lower forward P/E (16.4x vs 21.4x for STAAR Surgical).
Bausch + Lomb converts more of its revenue into profit, with a net margin of -7.1% versus -33.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLCO | STAA |
|---|---|---|
| Share price | $19.38 | $24.22 |
| Market cap | $6.93B | $1.22B |
| 1-day change | -6.33% | -3.24% |
| YTD return | +13.47% | +4.89% |
| 1-year return | +28.60% | -13.50% |
| 5-year return | — | -75.08% |
| Forward P/E | 16.36 | 21.39 |
| EPS (TTM) | $-0.32 | $0.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $5.10B | $239.44M |
| Revenue growth (YoY) | +6.47% | -23.72% |
| Net income (latest FY) | $-360.00M | $-80.45M |
| Gross margin | — | 76.19% |
| Operating margin | 2.22% | -38.30% |
| Net margin | -7.06% | -33.60% |
| 52-week high | $21.40 | $35.87 |
| 52-week low | $14.65 | $15.59 |
| Distance from 52-week high | -9.44% | -32.48% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +13.16% | +17.92% |
| Average volume | 660.67K | 835.89K |
| Shares outstanding | 357.50M | 50.20M |
| Employees | 13,000 | 921 |
| Sector | Health Care | Health Care |
| Industry | Ophthalmic Goods | Ophthalmic Goods |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Bausch + Lomb is about 5.7 times larger than STAAR Surgical by market value ($6.93B vs $1.22B).
- BLCO has outperformed STAA by 42.1 percentage points over the past year.
- Bausch + Lomb is more profitable, keeping -7.1 cents of every revenue dollar as net income versus -33.6 cents for STAAR Surgical.
- Bausch + Lomb grew revenue faster in its latest fiscal year (+6.47% vs -23.72%).
About Bausch + Lomb
BLCO stock →Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical.
Health Care · Ophthalmic Goods · 13,000 employees
About STAAR Surgical
STAA stock →STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.
Health Care · Ophthalmic Goods · 921 employees
BLCO vs STAA FAQ
Which is bigger, Bausch + Lomb or STAAR Surgical?
Bausch + Lomb (BLCO) is larger, with a market capitalization of $6.93B compared with $1.22B for STAAR Surgical (STAA).
Which stock has performed better over the past year, BLCO or STAA?
BLCO returned +28.60% over the past 12 months, compared with -13.50% for STAA (price return, excluding dividends). Past performance does not predict future results.
Are Bausch + Lomb and STAAR Surgical in the same industry?
Yes. Both are classified in the Ophthalmic Goods industry within the Health Care sector.